Structure and interactions of aspirin-like drugs

  • M. Vijayan


A pre-requisite for the elucidation of the mechanism of action of aspirin-like drugs, which are believed to exert their pharmacological effects through the inhibition of prostaglandin biosynthesis, is an understanding of their molecular geometry, the non-covalent interactions they are likely to be involved in, and the geometrical and the electronic consequences of such interactions. This has been sought to be achieved through the x-ray analysis of these drug molecules and their crystalline complexes with other suitable molecules. The results obtained from such studies have been discussed in terms of specific typical examples. For instance, antipyrine can form metal and hydrogen-bonded complexes; phenylbutazone can form ionic complexes with basic molecules. Complex formation is accompanied by characteristic changes in the molecular geometry and the electronic structure in both the cases. The results obtained so far appear to indicate that the important common invariant structural features of the fenamates, deduced from crystal structures, are retained even when complexation takes place.


Aspirin-like drugs prostaglandin biosynthesis non-covalent interactions crystalline complexes pyrazole derivaties fenamates 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Brassy C, Michaud M C, Delettre J and Mornon J P 1974aActa Crystallogr. B30 2848Google Scholar
  2. Brassy C, Mornon J P and Delettre J 1974bActa Crystallogr. B30 2243Google Scholar
  3. Brassy C, Mornon J P, Delettre J and Lepicard G 1974cActa Crystallogr. B30 2500Google Scholar
  4. Brassy C, Renaud A, Delettre J and Mornon J P 1974dActa Crystallogr. B30 2246Google Scholar
  5. Cingi M B, Gaustini C, Musatti A and Nardelli M 1972Acta Crystallogr. B28 667Google Scholar
  6. Dhanaraj V and Vijayan M 1983Acta Crystallogr. (in press)Google Scholar
  7. Flower R J 1974Pharmocol. Rev. 26 33Google Scholar
  8. Krishna Murthy H M and Vijayan M 1979Acta Crystallogr. B35 262Google Scholar
  9. Krishna Murthy H M and Vijayan M 1981aActa Crystallogr. B37 210Google Scholar
  10. Krishna Murthy H M and Vijayan M 1981bActa Crystallogr. B37 1102Google Scholar
  11. Krishna Murthy H M, Bhat T N and Vijayan M 1982Acta Crystallogr. B38 315Google Scholar
  12. Krishna Murthy H M, Vijayan M and Brehm L 1979Acta Crystallogr. B35 612Google Scholar
  13. McConnell J F 1973Cryst. Struct. Commun. 2 459Google Scholar
  14. McConnell J F and Company F Z 1976Cryst. Struct. Commun. 5 861Google Scholar
  15. Salunke D M and Vijayan M 1981Int. J. Peptide Protein Res. 18 348CrossRefGoogle Scholar
  16. Singh T P and Vijayan M 1973Acta Crystallogr. B29 714Google Scholar
  17. Singh T P and Vijayan M 1974Acta Crystallogr. B30 557Google Scholar
  18. Singh T P and Vijayan M 1976Acta Crystallogr. B32 2432Google Scholar
  19. Singh T P and Vijayan M 1977J. Chem. Soc. Perkin Trans. 2 p. 693Google Scholar
  20. Sudhakar V, Bhat T N and Vijayan M 1980Acta Crystallogr. B36 125Google Scholar
  21. Suresh C G and Vijayan M 1983aInt. J. Peptide Protein Res. 21 223; and the references thereinCrossRefGoogle Scholar
  22. Suresh C G and Vijayan M 1983bInt. J. Peptide Protein Res. 22 129CrossRefGoogle Scholar
  23. Toussaint J, Dideberg O and Dupont L 1974Acta Crystallogr. B30 590Google Scholar
  24. Vane J R 1971Nature New Biology 231 232Google Scholar
  25. Vijayan M 1980FEBS Lett. 112 135CrossRefGoogle Scholar
  26. Vijayan M 1983 inConformation in biology (eds) R Srinivasan and R H Sarma (New York: Adenine Press) p. 175Google Scholar
  27. Vijayan M and Viswamitra M A 1966Acta Crystallogr. 21 522CrossRefGoogle Scholar
  28. Vijayan M and Viswamitra M A 1967Acta Crystallogr. 23 1000CrossRefGoogle Scholar
  29. Vijayan M and Viswamitra M A 1968Acta Crystallogr. B24 1067Google Scholar

Copyright information

© Printed in India 1983

Authors and Affiliations

  • M. Vijayan
    • 1
  1. 1.Molecular Biophysics UnitIndian Institute of ScienceBangaloreIndia

Personalised recommendations